Recombinant Cynomolgus DNAM-1/CD226 Fc Chimera Protein, CF

When Recombinant Cynomolgus Monkey DNAM-1/CD226 Fc Chimera(Catalog # 9276-DN) is immobilized at 0.25 μg/mL, 100 μL/well, Recombinant Human CD155/PVR FcChimera (Catalog # 9174-CD) binds with a typical ED50 of0.2-1 μg/mL.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus DNAM-1/CD226 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Cynomolgus Monkey DNAM-1/CD226 Fc Chimera is immobilized at 0.25 μg/mL (100 μL/well), the concentration of Recombinant Human CD155/PVR Fc Chimera (Catalog # 9174-CD) that produces 50% of the optimal binding response is approximately
  0.2-1 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived cynomolgus monkey DNAM-1/CD226 protein
  

  Cynomolgus Monkey DNAM-1/CD226 (Glu19-Asn247) Accession # XP_005586537	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: XP_005586537
• N-terminal Sequence: Glu19
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 53 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 74-87 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 1 mg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus DNAM-1/CD226 Fc Chimera Protein, CF

• CD226 antigenplatelet and T cell activation antigen 1
• CD226 molecule
• CD226
• DNAM1
• DNAM-1
• DNAM1adhesion glycoprotein
• DNAM-1DNAX accessory molecule-1
• DNAX accessory molecule 1
• PTA1
• T lineage-specific activation antigen 1 antigen
• TLiSA1

Background

DNAX accessory molecule-1 (DNAM-1), also known as CD226, is a 65 kDa type I transmembrane glycoprotein in the immunoglobulin superfamily (1). Mature cynomolgus DNAM-1 contains a 236 amino acid (aa) extracellular domain (ECD) with two Ig-like C2-set domains and a 61 aa cytoplasmic region that contains motifs for binding PDZ domains and band 4.1 family proteins (1, 2). Within the ECD, cynomolgus DNAM-1 shares 93%, 53% and 50% aa sequence identity with human, mouse, and rat DNAM-1, respectively. DNAM-1 is expressed on multiple lymphoid, myeloid cells, and activated vascular endothelial cells and interacts with CD155/PVR and Nectin-2/CD112 (3-5). It competes with CD96 and TIGIT for binding to these proteins (6). It associates in cis with Integrin beta 2/CD18 on activated, but not resting, NK, T, and mast cells (5, 7, 8). Ligation of DNAM-1 promotes the activation of NK cells, CD8⁺ T cells, and mast cells (2-4, 7, 9), Th17 polarization (10), dendritic cell maturation, megakaryocyte, and activated platelet adhesion to vascular endothelial cells, and monocyte extravasation; it also inhibits the formation of osteoclasts (11-14). Platelet-endothelium interactions mediated by DNAM-1 enable the metastasis of tumor cells to the lung (15). Downregulation of DNAM-1 on tumor cells can interfere with anti-tumor cellular immunity (16).

1. Ceboni, C. et al. (2013) Front. Immunol. 4:508.
2. Shibuya, A. et al. (1996) Immunity 4:573.
3. Bottino, C. et al. (2003) J. Exp. Med. 198:557.
4. Tahara-Hanaoka, S. et al. (2004) Int. Immunol. 16:533.
5. Kojima, H. et al. (2003) J. Biol. Chem. 278:36748.
6. Chan, C.J. et al. (2014) Nat. Immunol. 15:431.
7. Bachelet, I. et al. (2006) J. Biol. Chem. 281:27190.
8. Shibuya, K. et al. (1999) Immunity 11:615.
9. Dardalhon, V. et al. (2005) J. Immunol. 175:1558.
10. Lozano, E. et al. (2013) J. Immunol. 191:3673.
11. Reymond, N. et al. (2004) J. Exp. Med. 199:1331.
12. Kakehi, S. et al. (2007) Mol. Cell. Biochem. 301:209.
13. Kojima, H. et al. (2003) J. Biol. Chem. 278:36748.
14. Tahara-Hanaoka, S. et al. (2006) Blood 107:1491.
15. Morimoto, K. et al. (2007) Oncogene 27:264.
16. Carlsten, M. et al. (2009) J. Immunol. 183:4921.

Bioinformatics

• Uniprot:
  • XP_005586537()